GLAXF News and Press, GlaxoSmithKline Plc From 04/07/20

Musings Shorter update this month since life is too crazy to look backwards at the moment, plus I made a ton of trades to report (so no gory graphs demonstrating the pain I am sure that your portfolio dashboard is telling you). I don’t believe that any of the posted numbers (espec...

GlaxoSmithKline's Nucala Achieves Co-Primary Endpoints GlaxoSmithKline ( GSK ) announced that its drug candidate Nucala met co-primary endpoints for the pivotal SYNAPSE study. The trial was designed to assess the efficacy of this asthma drug in treating patients with nasal polyps associa...

New York City, NY:March 27, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Color Ultrasonic Diagnostic Apparatus Market in Global Industry: 2020 Research and New Innovations in Medical Devices Sector. The prime objective of the report is to ...

New York City, NY:March 27, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Chemical Mechanical Planarization Slurries Market in Global Industry: 2020 Research and New Innovations in Chemicals and Materials Sector. The prime objective of the ...

New York City, NY:March 27, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Consumer Healthcare Market in Global Industry: 2020 Research and New Innovations in Medical Devices Sector. The prime objective of the report is to offer updates and ...

This article is first in a series that provides an ongoing analysis of the changes made to Ariel Investments' 13F stock portfolio on a quarterly basis. It is based on Ariel Investments' regulatory 13F Form filed on 02/14/2020. John Rogers' 13F portfolio value increased ~6% from $7.51B to $7....

This article is part of a series that provides an ongoing analysis of the changes made to Tweedy Browne's 13F portfolio on a quarterly basis. It is based on Tweedy Browne's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking Tweedy Browne Portfolio series to get an idea of t...

Quick Take Lyra Therapeutics ( LYRA ) has filed to raise $57.5 million in an IPO of its common stock, according to an S-1 registration statement . The company is advancing a pipeline of treatment candidates for chronic rhinosinusitis patients. LYRA is in Phase 2 trials for its lead cand...

Gilead Sciences (NASDAQ: GILD ) declined 3.84% yesterday. I believe that created a major buying opportunity as it's likely based on investors' (yet) limited understanding on Gilead’s strong positioning based on its anti-viral therapy Remdesivir in the battle agai nst COVID-19. The ...

Source: Barron's Gilead ( GILD ) reported a Q4 revenue of $5.88 billion, Non-GAAP EPS of $1.30 and GAAP EPS of $2.12. The stock is flat post-earnings. I have been bearish on Gilead for a few years now. The company's top line has gone through fits and starts and it will likely continue th...